The local ocular renin-angiotensin system, particularly the ACE2-Ang(1-7)-MasR axis, regulates intraocular pressure and represents a potential therapeutic target for glaucoma and other eye diseases.
The renin-angiotensin system (RAS), that is known for its role in the regulation of blood pressure as well as in fluid and electrolyte homeostasis, comprises dozens of angiotensin peptides and peptidases and at least six receptors. Six central components constitute the two main axes of the RAS cascade. Angiotensin (1-7), an angiotensin converting enzyme 2 and Mas receptor axis (ACE2-Ang(1-7)-MasR) counterbalances the harmful effects of the angiotensin II, angiotensin converting enzyme 1 and angiotensin II type 1 receptor axis (ACE1-AngII-AT1R) Whereas systemic RAS is an important factor in blood pressure regulation, tissue-specific regulatory system, responsible for long term regional changes, that has been found in various organs. In other words, RAS is not only endocrine but also complicated autocrine system. The human eye has its own intraocular RAS that is present e.g. in the structures involved in aqueous humor dynamics. Local RAS may thus be a target in the development of new anti-glaucomatous drugs. In this review, we first describe the systemic RAS cascade and then the local ocular RAS especially in the anterior part of the eye.
Holappa et al. (Mon,) conducted a review in Eye diseases (Glaucoma, Diabetic Retinopathy, Age-related Macular Degeneration, Retinopathy of Prematurity). Renin-angiotensin system (RAS) modulators was evaluated. The local ocular renin-angiotensin system, particularly the ACE2-Ang(1-7)-MasR axis, regulates intraocular pressure and represents a potential therapeutic target for glaucoma and other eye diseases.